Document Detail

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
MedLine Citation:
PMID:  22334369     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone.
Stephen A Harrison; Fayez M Hamzeh; Jian Han; Prashant K Pandya; Muhammed Y Sheikh; John M Vierling
Related Documents :
22796579 - Selective hepatic insulin resistance, very-low-density lipoprotein hypersecretion and h...
9496559 - Effect of octreotide on growth hormone, igf-i, igfbp-3, glucagon, cortisol and epinephr...
2887309 - On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients...
20946269 - A comparison of intermediate and long-acting insulins in people with type 2 diabetes st...
11251679 - No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration...
6246699 - Panhypopituitarism secondary to head trauma: evidence for a hypothalamic origin of the ...
20068149 - Insulin-mediated acceleration of breast cancer development and progression in a nonobes...
17192339 - Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test.
16625819 - Pathological mechanisms involved in diabetic neuropathy: can we slow the process?
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2012-06-11
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  56     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-26     Completed Date:  2012-10-11     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  464-73     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 American Association for the Study of Liver Diseases.
Division of Gastroenterology and Hepatology, Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  adverse effects
Diabetes Mellitus, Type 2 / drug therapy,  epidemiology
Drug Therapy, Combination
Follow-Up Studies
Hepacivirus / drug effects*,  genetics
Hepatitis C, Chronic / drug therapy*,  epidemiology,  virology
Hypoglycemic Agents / administration & dosage,  adverse effects
Insulin Resistance / physiology*
Interferon-alpha / administration & dosage*,  adverse effects
Liver Cirrhosis / epidemiology,  virology
Middle Aged
Polyethylene Glycols / administration & dosage*,  adverse effects
Recombinant Proteins / administration & dosage,  adverse effects
Ribavirin / administration & dosage*,  adverse effects
Risk Factors
Thiazolidinediones / administration & dosage*,  adverse effects
Treatment Outcome
Reg. No./Substance:
0/Antiviral Agents; 0/Hypoglycemic Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/Thiazolidinediones; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; X4OV71U42S/pioglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ZnO Coaxial Nanorod Homojunction UV Light-Emitting Diodes Prepared by Aqueous Solution Method.
Next Document:  Next-generation genetic testing for retinitis pigmentosa.